In an animal model of endotoxin induced diffuse lung injury, we propose to investigate the hypotheses that the pathogenesis of the injury involves oxidant injury to the lungs, an endotoxin induced proteinase/antiproteinase imbalance and alterations in cyclic nucleotide metabolism. Further, we propose that eicosanoids and platelet activating factor (PAF) released as part of the inflammatory response to endotoxemia mediate alterations in lung function and interactions of inflammatory cells with the lungs. To test these hypotheses, we propose studies which will measure lipid peroxidation products in blood and lung lymph and antioxidant enzymes in lung tissue after endotoxin and determine effects of exogenous antioxidants and induction of endogenous antioxidants on the endotoxin response. We will measure a panel of proteinases and antiproteinases in bronchoalveolar lavage (BAL) fluid, blood and lung lymph and determine effects of depletion (chloramine-T) or enhancement (alpha-1-antitrypsin) of antiproteinase activity on the responses of the lungs to endotoxemia. We will measure effects of endotoxin on release of eicosanoids and platelet activating factor in the lungs and determine effects of drugs which inhibit such release on the endotoxin reaction. We will collect lymphocytes and alveolar macrophages from sheep given endotoxin for in vitro measurements of chemotaxin, eicosanoid and PAF production. We will define the trafficking of neutrophils, lymphocytes (including subsets) and macrophages in blood, lung lymph, BAL fluid and lung tissue during the response to endotoxin and determine effects of interventions which alter the pathophysiology of the response on inflammatory cell traffic. We will determine the mechanism of suppression of the lungs' response to endotoxemia by prostaglandin E2. Finally, we will determine whether pharmacologic manipulation of cyclic nucleotide metabolism will prevent or reverse the increase in lung vascular permeability caused by endotoxemia. These studies, combined with others in this proposal, will permit a definition of the pathogenesis of endotoxin induced lung injury and demonstrate rational approaches for therapy and prevention which may be useful in humans.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Specialized Center (P50)
Project #
2P50HL019153-11
Application #
3943685
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
11
Fiscal Year
1987
Total Cost
Indirect Cost
Name
Vanderbilt University Medical Center
Department
Type
DUNS #
004413456
City
Nashville
State
TN
Country
United States
Zip Code
37203
Brigham, K L; Lane, K B; Meyrick, B et al. (2000) Transfection of nasal mucosa with a normal alpha1-antitrypsin gene in alpha1-antitrypsin-deficient subjects: comparison with protein therapy. Hum Gene Ther 11:1023-32
Conner, B D; Bernard, G R (2000) Acute respiratory distress syndrome. Potential pharmacologic interventions. Clin Chest Med 21:563-87
Mangialardi, R J; Martin, G S; Bernard, G R et al. (2000) Hypoproteinemia predicts acute respiratory distress syndrome development, weight gain, and death in patients with sepsis. Ibuprofen in Sepsis Study Group. Crit Care Med 28:3137-45
Brigham, K L; Stecenko, A A (2000) Gene therapy for acute lung injury. Intensive Care Med 26 Suppl 1:S119-23
Arons, M M; Wheeler, A P; Bernard, G R et al. (1999) Effects of ibuprofen on the physiology and survival of hypothermic sepsis. Ibuprofen in Sepsis Study Group. Crit Care Med 27:699-707
Peters, M T; Brigham, K L; King, G A et al. (1999) Optimization of cationic liposome-mediated gene transfer to human bronchial epithelial cells expressing wild-type or abnormal cystic fibrosis transmembrane conductance regulator (CFTR). Exp Lung Res 25:183-97
Wheeler, A P; Bernard, G R (1999) Treating patients with severe sepsis. N Engl J Med 340:207-14
Snapper, J R; Trochtenberg, D S; Hwang, Y S et al. (1999) Effect of pulmonary edema on tracheal diameter. Respiration 66:522-7
Dupont, W D; Plummer Jr, W D (1998) Power and sample size calculations for studies involving linear regression. Control Clin Trials 19:589-601
Clark, M P; Chow, C W; Rinaldo, J E et al. (1998) Multiple domains for initiator binding proteins TFII-I and YY-1 are present in the initiator and upstream regions of the rat XDH/XO TATA-less promoter. Nucleic Acids Res 26:2813-20

Showing the most recent 10 out of 202 publications